RxDoctor Payments Data

Tara Sanft, MD

Medical Oncology · New Haven, CTNPI 1730374562

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $2,222 of the $2,439 with a category attached, or 91.1%. Merck accounts for 82.0% of it on its own, with 1 other manufacturer making up the rest. That places this record below the midpoint for medical oncology clinicians in CT, where the typical reported total is $3,212.

$2,439in general payments, 2019–2025

Across 6 payments — averaging $406.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$2K
  • AstraZeneca$439
$292,301in research payments, 2019–2025

Across 11 payments — averaging $26,573 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$229K
  • Merck$59K
  • Pfizer$5K

What the payments were for

  • Speaking & faculty fees$2,22291%
  • Travel & lodging$2179%

General payments by program year

21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck1$2,000
AstraZeneca5$439

How this compares

$2,439 in reported general payments places this provider in the 45th percentile of 79 medical oncology providers in Connecticut.

See all medical oncology providers in Connecticut

Medicare billing

Part B allowed, 2024
$12,576
Medicare patients
94
Services billed
110

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Anastrozole51$792

Paid to pharmacies, not to this prescriber.

Other medical oncology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →